These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 25784706

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012.
    Cheng CM, Shin J, Guglielmo BJ.
    JAMA Intern Med; 2014 Oct; 174(10):1704-5. PubMed ID: 25127107
    [No Abstract] [Full Text] [Related]

  • 5. Bolstering the FDA's drug-safety authority.
    Schultz WB.
    N Engl J Med; 2007 Nov 29; 357(22):2217-9. PubMed ID: 18046024
    [No Abstract] [Full Text] [Related]

  • 6. Drug makers are still giving gifts to doctors, F.D.A. officials tell senators.
    Harris G.
    N Y Times Web; 2005 Mar 04; ():A15. PubMed ID: 15948332
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A primer of drug safety surveillance: an industry perspective. Part II: Product labeling and product knowledge.
    Allan MC.
    J Pharm Technol; 1992 Mar 04; 8(5):198-202. PubMed ID: 10171208
    [Abstract] [Full Text] [Related]

  • 10. FDA drug labeling for pregnancy and lactation drug safety monitoring systems.
    Greene MF.
    Semin Perinatol; 2015 Nov 04; 39(7):520-3. PubMed ID: 26428020
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M.
    Seton Hall Law Rev; 2007 Nov 04; 37(4):941-68. PubMed ID: 18363218
    [No Abstract] [Full Text] [Related]

  • 13. Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
    Jacobson JD, Feigal D.
    Food Drug Law J; 2007 Nov 04; 62(3):529-46. PubMed ID: 17915395
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Marketing off-label uses to physicians: FDA's draft (mis)guidance.
    Gass A, Wilson J.
    Am J Bioeth; 2008 Mar 04; 8(3):1-3. PubMed ID: 18570084
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
    Mello MM, Studdert DM, Brennan TA.
    N Engl J Med; 2009 Apr 09; 360(15):1557-66. PubMed ID: 19357413
    [No Abstract] [Full Text] [Related]

  • 19. Warning label limbo. FDA rule letting generic-drug makers update risk alerts draws heavy flak.
    Carlson J.
    Mod Healthc; 2014 Jun 30; 44(26):20-2. PubMed ID: 25134408
    [No Abstract] [Full Text] [Related]

  • 20. Pediatric exclusivity: evolving legislation and novel complexities within pediatric therapeutic development.
    Rivera DR, Hartzema AG.
    Ann Pharmacother; 2014 Mar 30; 48(3):369-79. PubMed ID: 24311725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.